Correlation of serum 25-hydroxyvitamin-D₃, hs-CRP, and homocysteine in women with gestational diabetes mellitus

Li Zhang, Huani Yi, Jie Li, Juan Dong

Department of Obstetrics and Gynecology, Jinan Maternity and Child Care Hospital, Jinan, China

Submitted: 15 October 2020
Accepted: 14 February 2021

Arch Med Sci
DOI: https://doi.org/10.5114/aoms/133347
Copyright © 2021 Termedia & Banach

Abstract

Introduction: To explore the changes and correlation of serum 25-hydroxyvitamin-D₃, high-sensitivity C-reactive protein (hs-CRP), and homocysteine (Hcy) in patients with gestational diabetes mellitus (GDM).

Material and methods: A total of 110 GDM patients from September 2019 to September 2020 constituted the GDM group, and 100 pregnant women with a normal 75 g oral glucose tolerance test (OGTT) throughout the same duration constituted the control group. General information of the patients was collected: maternal age, BMI, gravidity, parity, and the gestational week at the time of glucose tolerance screening. Serum levels of 25-(OH)₂-VitD₃, hs-CRP, and Hcy were compared between the two groups. Pearson correlation analysis was used to evaluate the correlation between 25-(OH)₂-VitD₃, hs-CRP, Hcy, and homeostasis model assessment of insulin resistance index (HOMA-IRI) in GDM patients.

Results: Serum 25-(OH)₂-VitD₃ levels in the GDM group and control group were 15.67 ±3.62 and 18.66 ±3.41 ng/ml, hs-CRP levels were 6.07 ±1.45 and 3.12 ±1.07 mg/l, and serum Hcy levels were 17.03 ±4.10 and 8.63 ±2.27 µmol/l. Serum 25-(OH)₂-VitD₃ levels in the GDM group were substantially lower than those in the control group, while hs-CRP, Hcy, and HOMA-IRI in the GDM group were significantly higher than those in the control group (p < 0.05). Pearson correlation analysis demonstrated that serum 25-(OH)₂-VitD₃ levels in the GDM group were negatively correlated with HOMA-IRI. In contrast, hs-CRP and Hcy levels were substantially positively correlated with HOMA-IRI (p < 0.01).

Conclusions: Blood levels of 25-(OH)₂-VitD₃, hs-CRP, and Hcy levels can be a potential indicator of GDM.

Key words: gestational diabetes mellitus, 25-hydroxyvitamin-D₃, high-sensitivity C-reactive protein, homocysteine.

Introduction

Pregnant women are mostly diagnosed with gestational diabetes mellitus (GDM) during the glucose tolerance screening at 24 to 28 weeks of gestation. The cause of the disease is currently unknown and may be related to genetic factors, early pregnancy diet, and placental insulin resistance [1, 2]. Studies [3, 4] have shown that the pathogenesis of GDM is closely associated with insulin resistance (IR), and it is considered one of the main pathogeneses of GDM. The latest research [5] revealed that some patients with type 2 diabetes have low vitamin D levels. Vitamin D
deficiency can affect insulin sensitivity by affecting the incidence of type 2 diabetes through immunological mechanisms. 25-hydroxyvitamin-D$_3$ (25-(OH)$_3$-VitD$_3$) is related to the decrease in overall insulin secretion and can be used as an indicator for early assessment of the vitamin D status of pregnant women [6–8]. Additionally, studies have demonstrated that inflammatory factors such as serum hypersensitive C-reactive protein (hs-CRP) and homocysteine (Hcy) are associated with the occurrence and development of type 2 diabetes [9–11]. This study aims to compare the differences in serum 25-(OH)$_3$-VitD$_3$, hs-CRP and Hcy levels between pregnant women with GDM and pregnant women with normal glucose tolerance, explore the correlation between the levels of 25-(OH)$_3$-VitD$_3$, hs-CRP, and Hcy and the pathogenesis of GDM, and clarify the specific roles of 25-(OH)$_3$-VitD$_3$, hs-CRP and Hcy in GDM, providing new ideas for GDM diagnosis and treatment.

Material and methods

General information

One hundred ten pregnant women with GDM from September 2019 to September 2020 comprised the GDM group, and 100 pregnant women with a normal 75 g oral glucose tolerance test (OGTT) throughout the same duration comprised the control group. General information of the patients, such as the age of pregnant women, gestational weeks at the time of glucose tolerance screening, body mass index (BMI) value, gravidity, and parity, was collected. The ethics committee of Jinan Maternity and Child Care Hospital approved this study.

Inclusion criteria

GDM group: (1) comply with the definition of GDM in the Guidelines for the Diagnosis and Treatment of Diabetes Mellitus in Pregnancy (2014) [12]: patients met 2 of the following indicators in the results of the 75 g OGTT at 24 to 28 weeks of pregnancy: fasting plasma glucose (FPG) ≥ 5.6 mmol/l, 1 h postprandial plasma glucose (1 hPG) ≥ 10.3 mmol/l, 2 hPG ≥ 8.6 mmol/l and 3 hPG ≥ 6.7 mmol/l; (2) GDM was diagnosed for the first time without targeted intervention; (3) cognitive function was normal; (4) signed the informed consent.

Control group: (1) all inspection results were within the normal range; (2) no history of GDM; (3) singleton pregnancy; (4) signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) patients with systemic infectious diseases; (2) patients with liver and kidney diseases that can cause fundamental lipid metabolism abnormalities; (4) patients with severe gastrointestinal dysfunction, leading to abnormal metabolism of basic vitamin D$_3$.

Indicators and methods of detection

The levels of serum 25-(OH)$_3$-VitD$_3$, hs-CRP, Hcy, and homeostasis model assessment of insulin resistance index (HOMA-IRI) were compared between two groups, and the correlations between serum 25-(OH)$_3$-VitD$_3$, hs-CRP, Hcy, and HOMA-IRI in GDM patients were analyzed.

Three milliliters of cubital venous blood was collected after fasting for 8 h in both groups. Centrifuged after standing, the upper serum samples were collected for testing, using the ELISA method (American Radu RT-6000 enzyme label instrument) to determine the serum 25-(OH)$_3$-VitD$_3$ level, and the relevant procedures were carried out in strict accordance with the instructions of the kit (Shanghai Hengyuan Biotechnology Co., Ltd.). Serum hs-CRP and Hcy levels were determined by fluorescence polarization immunoassay and immunoturbidimetry respectively, and the procedures were performed in strict accordance with the kit instructions (Shanghai Hengyuan Biotechnology Co., Ltd.). The fasting insulin (FINs) level was measured using the Beckman Coulter (China) UniCelDxi800 automatic chemiluminescence immunoassay analyzer, and the HOMA-IRI was calculated by the formula HOMA-IRI = FINs × FPG/22.5.

Statistical analysis

The SPSS Statistics package (version 26.0; IBM Corp., Armonk, NY) was used for all statistical analyses. All continuous variables data following data normal distribution were shown as the mean ± standard deviation. Statistical differences between the two sample means were assessed by the t-test for continuous variables, and the correlation analysis was performed by Person correlation analysis. All continuous variables’ data not following a normal distribution are expressed as median, 25th percentile, and 75th percentile. The Mann-Whitney U test was used for comparison between two groups, and the correlation analysis were assessed by Spearman correlation analysis. A value of $p < 0.05$ was considered statistically significant.

Results

General clinical data

Overall 210 patients were included in this study, comprising 110 cases in the GDM group.
and 100 cases in the control group. There were no significant differences between the two groups in maternal age, BMI, gravidity, parity, and the gestational weeks at the time of glucose tolerance screening (p > 0.05). The general clinical information of the patients is provided in Table I.

Comparison of 25-(OH)₂-VitD₃, hs-CRP, Hcy levels, and HOMA-IRI

Serum 25-(OH)₂-VitD₃ levels in the GDM group and control group were 15.67 ±3.62 ng/ml and 18.66 ±3.41 ng/ml, hs-CRP levels were 6.07 ±1.45 and 3.12 ±1.07 mg/l, and serum Hcy levels were 17.03 ±4.10 and 8.63 ±2.27 µmol/l. There were 42 cases of vitamin D deficiency in the GDM group, and the incidence of vitamin D insufficiency was 38.18% (42/110). There were 14 cases of vitamin D deficiency in the control group, and the incidence of vitamin D insufficiency was 14% (14/100). Between the two groups of subjects, serum 25-(OH)₂-VitD₃ levels in the GDM group were significantly lower than those in the control group. In contrast, hs-CRP, Hcy, and HOMA-IRI in the GDM group were substantially higher than those in the control group (p < 0.05) (Table II).

Correlation analysis of 25-(OH)₂-VitD₃, hs-CRP, Hcy levels, and HOMA-IRI

Pearson correlation analysis revealed that serum 25-(OH)₂-VitD₃ levels in the GDM group were negatively correlated with HOMA-IRI (r = –0.717, p < 0.05) (Figure 1), and hs-CRP levels were strongly positively correlated with HOMA-IRI (r = 0.781, p < 0.01) (Figure 2). There was a strong positive correlation between Hcy levels and HOMA-IRI (r = 0.790, p < 0.01) (Figure 3).

Discussion

At present, the pathogenesis of GDM is still unclear [13]. High insulin levels during pregnancy are one of the signs of IR. Changes in secretion and

| Group       | Cases | Age      | Gestational weeks at the time of glucose tolerance screening | BMI (kg/m²) | Gravidity | Parity |
|-------------|-------|----------|-------------------------------------------------------------|-------------|-----------|--------|
| GDM group   | 110   | 29.74 ±5.19 | 25.19 ±2.05                                               | 25.71 ±3.84 | 2.54 ±0.48 | 0.73 ±0.12 |
| Control group | 100   | 29.84 ±6.07 | 25.28 ±2.17                                               | 25.69 ±3.74 | 2.61 ±0.45 | 0.75 ±0.18 |
| Value of p  |       | 0.897    | 0.758                                                      | 0.969       | 0.278   | 0.341  |

BMI – body mass index, GDM – gestational diabetes mellitus.

| Group       | Cases | 25-(OH)₂-VitD₃ (ng/ml) | hs-CRP (mg/l) | Hcy (µmol/l) | HOMA-IRI |
|-------------|-------|------------------------|--------------|-------------|----------|
| GDM group   | 110   | 15.67 ±3.62            | 6.07 ±1.45   | 17.03 ±4.10 | 3.67 ±1.12 |
| Control group | 100   | 18.66 ±3.41            | 3.12 ±1.07   | 8.63 ±2.27  | 2.47 ±1.07 |
| Value of t  |       | 6.142                  | –19.968      | –18.570     | –7.963   |
| Value of p  |       | < 0.01                 | < 0.01       | < 0.01      | < 0.05   |

hs-CRP – high-sensitivity C-reactive protein, Hcy – homocysteine, HOMA-IRI – homeostasis model assessment of insulin resistance index, GDM – gestational diabetes mellitus.

![Figure 1](image1.png)  ![Figure 2](image2.png)

**Table I.** Comparison of general clinical data between the two groups (mean ± SD, n)

**Table II.** Comparison of serum 25-(OH)₂-VitD₃, hs-CRP, Hcy levels, and HOMA-IRI between the two groups (mean ± SD)

**Figure 1.** Scatter diagram of 25-(OH)₂-VitD₃ and HOMA-IRI

**Figure 2.** Scatter diagram of hs-CRP and HOMA-IRI
In this study, 25-(OH)2-VitD3, as the active ingredient of vitamin D in the serum of the GDM group, was substantially lower than that of the control group at the same pregnancy stage ($p < 0.05$) and negatively correlated with HOMA-IRI, suggesting that 25-(OH)2-VitD$_3$ deficiency is involved in the occurrence of GDM. The mechanism may be related to IR.

In recent years, studies [21] have revealed that GDM is closely related to inflammation, and low-level systemic chronic inflammation is one of the pathogeneses of GDM. Alamolhoda et al. [22] reported that inflammation can be associated with increased risk of GDM, and inflammatory factors such as CRP, IL, adiponectin, and TNF-$\alpha$ can affect the secretion of insulin by pancreatic islet B cells to increase blood glucose, leading to the occurrence of GDM [23]. Hyperglycemia caused by IR during pregnancy can stimulate the inflammatory cells in the body to release inflammatory factors. A variety of inflammatory factors play an essential function in the initiation and development of GDM [24]. hs-CRP is one of the most sensitive indicators of inflammation. When inflammation, trauma, and other diseases occur in the body, hs-CRP can increase significantly, which can be used as a potential indicator for GDM [25, 26]. Qiu et al. [27] conducted a prospective study on the relationship between serum hs-CRP and GDM in early pregnancy, and found that the relative risk of developing GDM in patients with elevated serum hs-CRP levels was 3.5 times higher than that of the control group. For every 1 mg/L increase in serum CRP, the risk of GDM increases by 20%. Hence, an increased hs-CRP level is one of the high-risk pathogenic factors of GDM and can be used as an indicator for early diagnosis of GDM. In our study we found that the serum hs-CRP levels of the GDM group were higher than those of the control group, suggesting that the serum hs-CRP levels of GDM patients were elevated. The serum hs-CRP levels were positively correlated with HOMA-IRI, implying that the higher the serum hs-CRP levels are, the higher is the HOMA-IRI. The levels of hs-CRP are related to the severity of GDM, and the levels of hs-CRP can indicate the occurrence and development of GDM.

Homocysteine (Hcy), as an intermediate product in methionine metabolism, has apparent vascular damage effects [28]. Increased Hcy concentration can induce oxidative stress through self-oxidation, which damages the function of vascular endothelial cells. It can cause microcirculation disorders by causing the aggregation and precipitation of lipoproteins, promoting platelet aggregation and thrombosis, participating in the pathophysiological process of decreased insulin secretion, and insulin resistance in diabetic patients [29, 30]. Vermeulen et al. [31] reported that Hcy levels were significantly increased in patients with GDM, which were near related to decreasing insulin sensitivity. In this study, the results showed that serum Hcy and HOMA-IR in the GDM group were substantially higher than those in the control group ($p < 0.05$). Correlation analysis showed a significant positive correlation between serum Hcy and HOMA-IRI ($p < 0.05$), indicating that elevated Hcy levels may cause IR, which is significant in the pathogenesis and progression of GDM.

In conclusion, the serum 25-(OH)$_2$-VitD$_3$ levels of GDM patients were significantly decreased, and...
CRP and Hcy levels were significantly increased, which may be relevant in the occurrence of GDM. Blood levels of 25-(OH)2-Vitamin D3, hs-CRP, and Hcy levels can be a potential indicator of GDM. Also, it is clinically possible to prevent and treat GDM through appropriate supplementation of vitamin D. Proper vitamin D supplementation can be used to prevent and treat GDM.

Conflict of interest
The authors declare no conflict of interest.

References
1. Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy. World Health Organization, Geneva 2013.
2. Radna V, Kanthimathi S, Anjana RM, Mohan V. Genetics of gestational diabetes mellitus. J Pak Med Assoc 2016; 66 (9 Suppl 1): S11-4.
3. Wang L, Zhang C, Song Y, Zhang Z. Serum vitamin D deficiency and risk of gestational diabetes mellitus: a meta-analysis. Arch Med Sci 2020; 16: 742-51.
4. Chieferi E, Arcidiacono B, Foti D, Brunetti A. Gestational diabetes mellitus: an updated overview. J Endocrinol Invest 2017; 40: 899-909.
5. Sacadote A, Dave P, Lokshin V, Baharri G. Type 2 diabetes mellitus, insulin resistance, and vitamin D. Curr Diab Rep 2019; 19: 101.
6. Zhang Y, Gong Y, Xue H, Xiong J, Cheng G. Vitamin D and gestational diabetes mellitus: a systematic review based on data free of Hawthorne effect. BioG 2018; 125: 784-93.
7. Shi A, Wen J, Liu G, et al. Genetic variants in vitamin D signaling pathways and risk of gestational diabetes mellitus. Oncotarget 2016; 7: 67788-95.
8. Triunfo S, Lanzona A, Lindqvist PG. Low maternal circulating levels of vitamin D as potential determinant in the development of gestational diabetes mellitus. J Endocrinol Invest 2017; 40: 1049-59.
9. Hu Y, Xu Y, Wang G. Homocysteine levels are associated with endothelial function in newly diagnosed type 2 diabetes mellitus patients. Metab Syndr Relat Disord 2019; 17: 323-7.
10. Adab Z, Eghtesadi S, Vafa MR, et al. Effect of turmeric on glycemic status, lipid profile, hs-CRP, and total antioxidant capacity in hyperlipidemic type 2 diabetes mellitus patients. Phytother Res 2019; 33: 1173-81.
11. Radzicka S, Ziolekowska K, Zaborowski MP, Brazert J, Pietryga M. Serum homocysteine and vitamin B12 levels in women with gestational diabetes mellitus. Ginekol Pol 2019; 90: 381-7.
12. Association Obestrics Group of Obstetrics and Gynecology Branch of Chinese Medical. Guidelines for diagnosis and treatment of gestational diabetes mellitus (2014). Chin J Obstet Gynecol 2014; 49: 561-9.
13. American Diabetes Association. Improving care and promoting health in populations: standards of medical care in diabetes – 2020. Diabetes Care 2020; 43 (Suppl 1): S17-3.
14. Liu Y, Jin Q, Bao Y, Li S, Wang J, Qiu L. Investigation of the vitamin D nutritional status in women with gestational diabetes mellitus in Beijing. Lipids Health Dis 2017; 16: 22.
15. Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catralano PM, Friedman JE. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care 2007; 30 Suppl 2: S112-9.
16. Holick MF. The D-lightful vitamin D for child health. J Pediatr Enteral Nutr 2012; 36 (1 Suppl): 95-195.
17. Kim HS, Hwang HS, Kwon HS, Lim JY, Sohn IS. A comparative analysis of maternal and fetal 25-hydroxyvitamin D in pregnant women with and without gestational diabetes mellitus. J Matern Fetal Neonatal Med 2018; 31: 2748-55.
18. Boyle VT, Thorstensen EB, Mourath D, et al. The Relationship between 25-hydroxyvitamin D concentration in early pregnancy and pregnancy outcomes in a large, prospective cohort. Br J Nutr 2016; 116: 1409-15.
19. Jamilman M, Samimi M, Mirhosseini N, et al. A randomized double-blinded, placebo-controlled trial investigating the effect of fish oil supplementation on gene expression related to insulin action, blood lipids, and inflammation in gestational diabetes mellitus – fish oil supplementation and gestational diabetes. Nutrients 2018; 10: 163.
20. Mousa A, Abell SK, Shorakae S, et al. Relationship between vitamin D and gestational diabetes in overweight or obese pregnant women may be mediated by adiponectin. Mol Nutr Food Res 2017; 61.
21. Karpe TL, Money KM, Du L, et al. Sex modifies placental gene expression in response to metabolic and inflammatory stress. Placenta 2019; 78: 1-9.
22. Alamohoda SH, Yazdikhasti M, Namdari M, et al. Association between C-reactive protein and gestational diabetes: a prospective study. J Obstet Gynecol 2019; 118 (9 Suppl 1): S11-4.
23. Khorosowbeygi A, Rezvanfar MR, Ahmadvand H. Tumor necrosis factor-α, adiponectin and their ratio in gestational diabetes mellitus. Caspian J Intern Med 2018; 9: 71-9.
24. Yu N, Cui H, Chen X, Chang Y. Changes of serum pentraxin-3 and hypersensitive CRP levels during pregnancy and their relationship with gestational diabetes mellitus. PLoS One 2019; 14; e0224739.
25. Ahi Z, Kariman N, Asl SZ, Shakeri N. Diagnostic value of C-reactive protein in determining of gestational diabetes mellitus (GDM). Biosci Biotechnol Res Asia 2016; 13: 743e50.
26. Amirian A, Rahmehnai FA, Abdil F. Role of C-reactive protein (CRP) or high-sensitivity CRP in predicting gestational diabetes mellitus: systematic review. Diabetes Metab Syndr 2020; 14: 229-36.
27. Qiu C, Sorensen TK, Luthy DA, Williams MA. A prospective study of maternal serum C-reactive protein (CRP) concentrations and risk of gestational diabetes mellitus. Paediatr Perinat Epidemiol 2004; 18: 377-84.
28. Molęda P, Fronczyk A, Safranow K, Majkowska L. Homocysteine levels in women with a history of gestational diabetes. Pharm Sci Monit 2015; 16: 594-8.
29. Cui H, Chen X, Chang Y. Changes of serum pentraxin-3 and hypersensitive CRP levels during pregnancy and their relationship with gestational diabetes mellitus. PLoS One 2019; 14: e0224739.
30. Ahi Z, Kariman N, Asl SZ, Shakeri N. Diagnostic value of C-reactive protein in determining of gestational diabetes mellitus (GDM). Biosci Biotechnol Res Asia 2016; 13: 743e50.
31. Vermeulen EG, Stehouwer CD, Valk J, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B on cerebrovascular atherosclerosis and white matter abnormalities as determined by MRI and MRT: a placebo-controlled, randomized trial. Eur J Clin Invest 2004; 34: 256-61.